Clinical trials: Neoadjuvant Therapy
Pheochromocytoma, Paraganglioma
A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL
This phase II trial studies the effectiveness oftemozolomide in the neoadjuvant therapy oflocally advanced,or unresectable pheochromocytoma or paragangliom(PPGL).
- Trial name
- NCT05885386
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Rectal Cancer, Oncology
Outcomes of Neoadjuvant Therapy for Rectal Cancer in a Tertiary Asian Institute
This is a retrospective cohort study that aims to evaluate the correlation of magnetic resonance tumour regression grade (mrTRG) and pathological TRG (pTRG) of locally advanced rectal cancer after neoadjuvant long course…
- Trial name
- NCT05607186
- Testing
- neoadjuvant long course chemoradiotherapy
- Volunteers
- 59 people
- Sponsor
- Singapore General Hospital
Melanoma, Skin
Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node
Rationale: The randomized trial NADINA has demonstrated that neoadjuvant treatment with nivolumab with ipilimumab improves event-free survival (EFS) in patients with macroscopic resectable stage III melanoma.
- Trial name
- OMIT (NCT06754904)
- Testing
- Omitting TLND, Index node procedure
- Where
- Netherlands
- Volunteers
- 213 people
- Sponsor
- D.J. (Dirk) Grünhagen
Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
This study aims to evaluate the effectiveness and safety of a preoperative treatment (called neoadjuvant therapy) combining four drugs-nab-paclitaxel, oxaliplatin, S-1, and sintilimab-for patients with locally advanced…
- Conditions
- Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced
- Trial name
- YOUNG-NEOS (NCT07018063)
- Testing
- nab-paclitaxel, oxaliplatin, S-1
- Where
- China
- Volunteers
- 35 people
- Sponsor
- zhoujing
Breast Neoplasms, Breast Cancer
Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers
A correlation between early changes in the tumor maximum standardized uptake value (SUVmax) on FDG-PET after one or two cycles of neoadjuvant chemotherapy (NAC) and the pathological response after 6 to 8 cycles has been…
- Trial name
- NCT02600442
- Testing
- non interventional study
- Where
- France
- Volunteers
- 168 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hyperthermic Intraperitoneal Chemotherapy, Neoadjuvant Chemotherapy
Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the NHIPEC Trial)
Background: Neoadjuvant chemotherapy (NACT) is an important treatment option for patients with ovarian cancer. Although intravenous NACT can improve optimal resection rates and decrease surgical morbidity and mortality, these…
- Trial name
- NHIPEC (NCT05246020)
- Testing
- HIPEC, intravenous chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Neoplasms
Single-cell RNAseq Breast Cancer
Molecular characterization of persistent tumor cells remaining after NAC and infiltrating immune cells, for example, M2 macrophages, could strongly contribute to identifying targeted therapeutic approaches for this disease.
- Trial name
- SCRBC (NCT05807516)
- Testing
- Single-cell RNA sequencing (scRNAseq), whole-exome sequencing (WES)
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Regina Elena Cancer Institute
Ewing Sarcoma
Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma
This single-center prospective observational study aims to evaluate whether longitudinal changes in serum pro-gastrin-releasing peptide (ProGRP) reflect treatment response in patients with newly diagnosed Ewing sarcoma.
- Trial name
- NCT07725783
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Autologous Stem Cell Transplantation: International Lupus Trial
The purpose of this study is to evaluate remission induction therapy for refractory Lupus Erythematosus with autologous hematopoietic stem cell transplantation (AHSCT) versus Rituximab (anti CD20) followed by maintenance therapy…
- Trial name
- ASTIL (NCT05063513)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Rituximab
- Where
- France
- Sponsor
- European Society for Blood and Marrow Transplantation
Ganglioneuroblastoma, Localized Resectable Neuroblastoma
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
This pilot clinical trial studies induction therapy followed by iobenguane I 131 and chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma undergoing stem cell transplant, radiation therapy, and…
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT01175356
- Testing
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan
- Where
- 25 sites in United States
- Volunteers
- 99 people
- Sponsor
- Children's Oncology Group
Rectal Cancer
Expression of Molecular Markers Before and After Neo-adjuvant Chemoradiotherapy in Rectal Cancer
The purpose of this study is to determine whether markers on tumor tissue may be an indicator for good response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
- Trial name
- NCT00835055
- Where
- Switzerland
- Sponsor
- St. Claraspital AG
Brain Tumor, Central Nervous System Tumors
Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it is no longer present by…
- Conditions
- Brain Tumor, Central Nervous System Tumors, Childhood Germ Cell Tumor
- Trial name
- NCT00047320
- Testing
- carboplatin, etoposide, ifosfamide
- Where
- 106 sites in United States, Australia and 3 more
- Volunteers
- 104 people
- Sponsor
- Children's Oncology Group
HGSOC
Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings
To compare DHODH protein expression in HGSC tissues from patients undergoing Primary Debulking Surgery (PDS - Chemo-naive) versus Interval Debulking Surgery (IDS - Post-NACT).
- Trial name
- HGSOC (NCT07366242)
- Testing
- Immunohistochemical (IHC) assessment of DHODH expression, No interventions as it is observational study
- Where
- Egypt
- Volunteers
- 72 people
- Sponsor
- Heba Ahmed Mohamed
Breast Cancer
Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.
Seventy per cent of breast cancers express estrogen (ER) and progesterone receptors (PR) and respond to endocrine treatment. Actual therapy targets ER.
- Trial name
- MIPRA (NCT02651844)
- Testing
- Mifepristone
- Where
- Argentina
- Volunteers
- 20 people
- Sponsor
- Hospital Provincial Magdalena V. de Martínez
Locally Advanced Rectal Cancer
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer
The study evaluates the addition of immunotherapy of PD-1 antibody in neoadjuvant chemoradiotherapy in microsatellite stability-high (MSI-H) locally advanced rectal cancer (LARC).
- Trial name
- NCT04411524
- Testing
- PD-1 antibody, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Patients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction
Radiomics-based Models for the Prediction of Pathological Response to Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer
Identifying predictors of response to neoadjuvant therapy in gastric and gastro-oesophageal cancer early in the history of the disease would ensure optimal treatment planning.
- Trial name
- RADI-S (NCT06044961)
- Testing
- CT scan
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
This study is researching an experimental drug called cemiplimab (called "study drug") and the combination of experimental drugs of fianlimab and cemiplimab (called "study drugs").
- Trial name
- NCT07567469
- Testing
- Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC)
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Colorectal Cancer, Neoadjuvant Systemic Therapy
Survival Benefit of Primary Tumour Resection Compared to Systemic Therapy Alone in Stage IV Colorectal Cancer Patients
About 20-25 percent of all colorectal cancer patients are diagnosed with International Union Against Cancer (UICC) stage IV disease. The benefit of primary tumor resection in the palliative context is therefore of high concern.
- Trial name
- SurvSysT (NCT06326619)
- Testing
- Primary tumor resection, Systemic Therapy
- Volunteers
- 480 people
- Sponsor
- Medizinische Hochschule Brandenburg Theodor Fontane
Crohn Disease
Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease
The aim of the study is confirmation of efficacy of induction therapy with three doses of infliximab In patients with Crohn disease aged 7-17 years, and comparison of efficacy and safety of two regiment of maintenance therapy: 1.
- Trial name
- NCT01559142
- Testing
- Infliximab with azathioprine (IIFX + AZA), Infliximab (IFX alone)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Children's Memorial Health Institute, Poland
Pancreatic Cancer Resectable
Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer
Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.
- Trial name
- NCT06809374
- Testing
- gemcitabine
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kochi University